Publications & Reports

A survey of Australian general practitioners' hepatitis C knowledge and management 2 years after subsidised direct-acting antiviral therapy became available.

Gooey M, Wong E, Pedrana A, Allard N, Doyle J, Hellard M, Wade A
Disease Elimination Program, Burnet Institute, 85 Commercial Road, Melbourne, Vic. 3004, Australia.


In 2016, hepatitis C direct-acting antivirals (DAAs) became available in Australia. A group of general practitioners (GPs) were surveyed twice to assess hepatitis C knowledge and management; 191/1000 (19.1%) responded at baseline, 164/938 (17.5%) at follow up. Participants' mean Knowledge score increased: baseline 5.75 (95% CI 5.61-5.91), follow up 6.09 (95% CI 5.95-6.22; P <0.01). At follow up, 36/163 (22%) had prescribed DAAs compared with 23/187 (12%) at baseline (chi2(1) = 5.95, P = 0.02); however, 67/150 (45%) were unsure of treatment eligibility for people who inject drugs. Additional support for GPs is warranted to ensure optimal hepatitis C management in primary care.

Link to publisher’s web site


  • Journal: Sexual health
  • Published: 01/08/2020
  • Volume: 17
  • Issue: 4
  • Pagination: 387-389